Clinical Trial Update: Immunomodulatory Effects of IVIg on Pregnancy Rate of Patient With Recurrent Pregnancy Loss [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating immunomodulatory effects of IVIg on pregnancy rate in patients with recurrent pregnancy loss has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pregnancy Loss

Drugs mentioned

• IVIG (intravenous immunoglobulin)

Snippet

Sponsor: Tabriz University of Medical Sciences | Conditions: Recurrent Pregnancy Loss | Phase 2 | Status: COMPLETED